Federica Giugliano

Dr. Federica Giugliano

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
PTPaolo Tarantino
Paolo Tarantino
Sara GandiniSara Gandini
Sara Gandini
ENEleonora Nicolò
Eleonora Nicolò
PAPamela Trillo Aliaga
Pamela Trillo Aliaga
FGFederica Giugliano
Federica Giugliano
GCGiuseppe Curigliano
Giuseppe Curigliano

27 March 2023 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
CCChiara Corti
Chiara Corti
FGFederica Giugliano
Federica Giugliano
ENEleonora Nicolò
Eleonora Nicolò
PTPaolo Tarantino
Paolo Tarantino
CCCarmen Criscitiello
Carmen Criscitiello
GCGiuseppe Curigliano
Giuseppe Curigliano

9 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CCChiara Corti
Chiara Corti
FGFederica Giugliano
Federica Giugliano
ENEleonora Nicolò
Eleonora Nicolò
LALiliana Ascione
Liliana Ascione
GCGiuseppe Curigliano
Giuseppe Curigliano
Metastatic breast cancer (BC) is currently an incurable disease. Besides endocrine therapy and targeted agents, chemotherapy is often used in the treatment of this disease. However, lack of tumor specificity and toxicity associated with dose exposure limit the manageability of cytotoxic agents. Antibody–drug conjugates (ADCs) are a relatively new class of anticancer drugs. By merging the selectivity of monoclonal antibodies with the cytotoxic properties of chemotherapy, they improve the therapeutic index of antineoplastic agents. Three core components characterize ADCs: the antibody, directed to a target antigen; the payload, typically a cytotoxic agent; a linker, connecting the antibody to the payload. The most studied target antigen is HER2 with some agents, such as trastuzumab deruxtecan, showing activity not only in HER2-positive, but also in HER2-low BC patients, possibly due to a bystander effect. This property to provide a cytotoxic impact also against off-target cancer cells may overcome the intratumoral heterogeneity of some target antigens. Other cancer-associated antigens represent a strategy for the development of ADCs against triple-negative BC, as shown by the recent approval of sacituzumab govitecan. In this review, we discuss the current landscape of ADC development for the treatment of BC, as well as the possible limitations of this treatment.

31 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GAGabriele Antonarelli
Gabriele Antonarelli
FGFederica Giugliano
Federica Giugliano
CCChiara Corti
Chiara Corti
MRMatteo Repetto
Matteo Repetto
PTPaolo Tarantino
Paolo Tarantino
GCGiuseppe Curigliano
Giuseppe Curigliano
Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit aberrantly activated pathways and/or to unleash antigen (Ag)-specific immune responses. Nonetheless, mAb-mediated targeted pressure often fails due to escape mechanisms, mainly Ag loss/downregulation, ultimately providing therapy resistance. Hence, in order to target multiple Ag at the same time, and to facilitate cancer-immune cells interactions, bispecific antibodies (bsAbs) have been developed and are being tested in clinical trials, yielding variable safety/efficacy results based on target selection and their structure. While in hematologic cancers the bsAb blinatumomab recently reached the Food and Drug Administration (FDA)-approval for B Cell Acute Lymphoblastic Leukemia, bsAbs use in solid tumors faces considerable challenges, such as target Ag selection, biodistribution, and the presence of an immune-suppressive tumor microenvironment (TME). This review will focus on the state-of-the art, the design, and the exploitation of bsAbs against solid malignancies, delineating their mechanisms of action, major pitfalls, and future directions.

26 May 2023 in Genes
Verified
Journal Article
Open access
PDF file
Mariia IvanovaMariia Ivanova
Mariia Ivanova
FPFrancesca Maria Porta
Francesca Maria Porta
FGFederica Giugliano
Federica Giugliano
CFChiara Frascarelli
Chiara Frascarelli
Elham SajjadiElham Sajjadi
Elham Sajjadi
Nicola FuscoNicola Fusco
Nicola Fusco
Breast cancer is the most frequently diagnosed malignancy worldwide and the leading cause of cancer-related death among women. Brain metastases are a primary contributor to mortality, as they often go undetected until late stages due to their dormant nature. Moreover, the clinical management of brain metastases is complicated by the relevant issue of blood-brain barrier penetration. The molecular pathways involved in the formation, progression, and colonization of primary breast tumors and subsequent brain metastases are diverse, posing significant hurdles due to the heterogeneous nature of breast cancer subtypes. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. In this review, we aim to highlight the biological mechanisms of breast cancer brain metastases by evaluating multi-step genetic pathways and to discuss currently available and emerging treatment strategies to propose a prospective overview of the management of this complex disease.

22 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FGFederica Giugliano
Federica Giugliano
ASAmbra Carnevale Schianca
Ambra Carnevale Schianca
CCChiara Corti
Chiara Corti
Mariia IvanovaMariia Ivanova
Mariia Ivanova
NBNadia Bianco
Nadia Bianco
EMelisabetta munzone
elisabetta munzone
Approximately 15% of breast cancers are classified as HER2-positive, with an amplification of the ERBB2 gene and/or an overexpression of the HER2 protein. Up to 30% of HER2-positive breast cancers shows heterogeneity in HER2 expression and different patterns of spatial distribution, i.e., the variability in the distribution and expression of the HER2 protein within a single tumour. Spatial heterogeneity may potentially affect treatment, response, assessment of HER2 status and consequently, may impact on the best treatment strategy. Understanding this feature can help clinicians to predict response to HER2-targeted therapies and patient outcomes, and to fine tune treatment decisions. This review summarizes the available evidence on HER2 heterogeneity and spatial distribution and how this may affect current available treatment choices, exploring possible opportunities for overcoming this issue, such as novel pharmacological agents, belonging to the group of antibody–drug conjugates.